Showing results (91-100 of 171) with videos related to
Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|April 17, 2018
Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significancePetros Christopoulos, Marc A Schneider, Farastuk Bozorgmehr, et al.Translational Lung Cancer Research|December 4, 2018
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and cliniciansMichael Allgäuer, Jan Budczies, Petros Christopoulos, et al.Frontiers in Oncology|April 26, 2021
De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung CancerFarastuk Bozorgmehr, Daniel Kazdal, Inn Chung, et al.Journal of Pharmaceutical and Biomedical Analysis|February 19, 2026
Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studiesCoren Lahav, Nili Dahan, Michal Harel, et al.Annals of the Rheumatic Diseases|August 3, 2022
Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitorsKarolina Benesova, Franziska Viktoria Kraus, Rui A Carvalho, et al.European Journal of Cancer (Oxford, England : 1990)|September 14, 2024
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world studyGabriel Dernbach, Daniel Kazdal, Lukas Ruff, et al.Therapeutic Advances in Medical Oncology|February 22, 2021
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access programNikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, et al.International Journal of Cancer|September 22, 2018
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysisIvo Buchhalter, Eugen Rempel, Volker Endris, et al.Cancers|November 25, 2023
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion MutationsPetros Christopoulos, Nicolas Girard, Claudia Proto, et al.Frontiers in Oncology|July 16, 2021
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung CancerLea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, et al.Pageof 18